Touchstone Sands Capital US Select Growth ETF (TSEL) Dividend History

Company News

• SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

  SpyGlass Pharma, a private ophthalmic biotech company, raised $75 million in Series D funding to advance its drug delivery platform for glaucoma treatment through Phase III trials. The platform aims to provide multiple years of therapy, addressing the need for long-term management of chronic eye diseases.

  GlobeNewswire Inc.